Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Accumulated Expenses: 2023-2025

Historic Accumulated Expenses for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Mar 2025 value amounting to $8.0 million.

  • Monte Rosa Therapeutics' Accumulated Expenses rose 126.76% to $8.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.0 million, marking a year-over-year increase of 126.76%. This contributed to the annual value of $8.2 million for FY2024, which is 8.26% up from last year.
  • Monte Rosa Therapeutics' Accumulated Expenses amounted to $8.0 million in Q1 2025, which was down 2.37% from $8.2 million recorded in Q4 2024.
  • Monte Rosa Therapeutics' 5-year Accumulated Expenses high stood at $8.2 million for Q4 2024, and its period low was $3.2 million during Q1 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Accumulated Expenses value was $6.1 million (recorded in 2023), while the average stood at $6.0 million.
  • Data for Monte Rosa Therapeutics' Accumulated Expenses shows a peak YoY spiked of 126.76% (in 2025) over the last 5 years.
  • Over the past 3 years, Monte Rosa Therapeutics' Accumulated Expenses (Quarterly) stood at $7.6 million in 2023, then climbed by 8.26% to $8.2 million in 2024, then surged by 126.76% to $8.0 million in 2025.
  • Its Accumulated Expenses stands at $8.0 million for Q1 2025, versus $8.2 million for Q4 2024 and $7.1 million for Q3 2024.